249 related articles for article (PubMed ID: 1539329)
1. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
2. Five-year experience with a triple drug protocol in renal transplantation.
Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
[No Abstract] [Full Text] [Related]
3. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
4. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
[No Abstract] [Full Text] [Related]
5. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
6. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
7. Prophylaxis with a short course of OKT3 in renal transplantation: comparative analysis with recipients treated either with prophylactic ATG or with CyA.
Lloveras J; Puig JM; Oliveras A; Orfila A; Comerma I; Aubia J; Masramón J
Transplant Proc; 1992 Feb; 24(1):43-4. PubMed ID: 1539335
[No Abstract] [Full Text] [Related]
8. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival.
Howard RJ; Pfaff WW; Brunson ME; Ramos EL; Peterson JC; Croker BP; Scornik JC; Parris CJ; Fennell RS
Transplant Proc; 1993 Feb; 25(1 Pt 2):884. PubMed ID: 8442256
[No Abstract] [Full Text] [Related]
9. Strategy for improving retransplantation in the CyA era.
Dickerman R; Langley J; Brinker K; Trevino G; Melton L; Vergne-Marini P; Wilson PK
Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
[No Abstract] [Full Text] [Related]
10. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts.
Broyer M; Gagnadoux MF; Guest G; Arsan A; Beurton D; Revillon Y; Niaudet P
Transplant Proc; 1993 Feb; 25(1 Pt 1):570-1. PubMed ID: 8438418
[No Abstract] [Full Text] [Related]
11. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
12. Cyclosporine monotherapy versus OKT3 and cyclosporine versus prednisone and cyclosporine as induction therapy in older renal transplant patients: a multicenter randomized study. Spanish Monotherapy Study Group.
Transplant Proc; 1994 Oct; 26(5):2522-4. PubMed ID: 7940775
[No Abstract] [Full Text] [Related]
13. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
[TBL] [Abstract][Full Text] [Related]
14. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
15. [Antilymphocyte serum, cyclosporine and corticoids, versus OKT3, cyclosporine, and corticoids in kidney transplantation].
Grino JM; Castelao AM; Seron D; Gonzalez C; Gil-Vernet S; Andres E; Bover J; Mestre M; Alsina J
Presse Med; 1991 Nov; 20(40):2039-42. PubMed ID: 1837121
[TBL] [Abstract][Full Text] [Related]
16. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
[No Abstract] [Full Text] [Related]
17. Renal allograft function and results with cyclosporine immunosuppression in recipients of single kidneys from cadaveric donors aged 12 to 24 months.
Banowsky LH; Wright FH; Kothmann R; Floyd M; Vick S
Transplant Proc; 1996 Aug; 28(4):2121-4. PubMed ID: 8769175
[No Abstract] [Full Text] [Related]
18. Optimization of cyclosporine monotherapy--long-term graft function.
Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
[No Abstract] [Full Text] [Related]
19. Adjuncts to triple-drug therapy after cardiac transplantation: a comparison of Nashville rabbit antithymocyte serum to OKT3.
Aziz S; Kruse AP; Roby PV; Allen MD; Khan K; Fishbein D
Transplant Proc; 1994 Oct; 26(5):2721-3. PubMed ID: 7940852
[No Abstract] [Full Text] [Related]
20. Renal transplantation with cyclosporine in the elderly population.
Velez RL; Brinker KR; Vergne-Marini PJ; Nesser DA; Long DL; Trevino G; Dickerman RM; Helfrich GB
Transplant Proc; 1991 Apr; 23(2):1749-52. PubMed ID: 1905073
[No Abstract] [Full Text] [Related]
[Next] [New Search]
